GLP-1 Medications and Weight Loss: New Research Shows They Work Across Diverse Patients – With One Important Difference for Women
At Affinity Whole Health, we prescribe compounded GLP-1 receptor agonists (such as semaglutide and tirzepatide) to many patients seeking sustainable weight loss and better metabolic health. One question we often hear is: “Do these medications work the same for everyone?” A major new study published in JAMA Internal Medicine provides reassuring, high-quality answers.
What the Landmark Study Found
Researchers conducted a systematic review and meta-analysis of 41 articles representing 64 randomized controlled trials involving GLP-1 receptor agonists (including semaglutide, liraglutide, dulaglutide, and others). They specifically examined whether treatment effects varied by age, sex, race and ethnicity, baseline body mass index (BMI), or baseline hemoglobin A1c (HbA1c).
The results were clear and clinically meaningful:
Greater weight loss in women than men: Women experienced an average 10.9% weight reduction compared to 6.8% in men.
No meaningful differences across other key groups: The medications produced consistent weight loss regardless of age, race, ethnicity, starting BMI, or starting blood sugar control (HbA1c).
In other words, GLP-1 therapy is broadly effective across diverse patient populations – a finding that supports personalized use without major adjustments based on most demographic or clinical factors.
Why the Sex Difference? The Estrogen Connection
The authors postulate that the greater response in women may be related to estrogen. They note that GLP-1 medications may interact synergistically with estrogen and that women’s typically lower body weight could influence how the drug is processed in the body.
This hypothesis aligns beautifully with other recent real-world evidence on menopausal hormone therapy (MHT). Multiple studies have now shown that postmenopausal women who are on MHT (estrogen-containing hormone therapy) lose significantly more weight and fat when using GLP-1 medications compared to women not on MHT.
For example:
In one study of postmenopausal women using semaglutide, those also on hormone therapy achieved 16% total body weight loss at 12 months versus 12% in women not on hormone therapy.
A 2026 retrospective cohort study specifically on tirzepatide found that postmenopausal women using concurrent MHT lost 19.2% of their body weight compared to 14.0% in those using tirzepatide alone (a relative difference of approximately 35% greater weight loss).
Important Note on MHT: Menopausal hormone therapy is recommended only for women experiencing perimenopausal or menopausal symptoms (such as hot flashes, night sweats, or vaginal dryness) and is not used for weight loss alone. It must be carefully evaluated based on your individual health history, risks, and benefits.
What This Means for Our GLP-1 Patients
This research is highly encouraging for several reasons:
If you are a man, woman, younger adult, older adult, or from any racial or ethnic background, GLP-1 therapy remains a powerful, evidence-based option.
The consistent effects across most subgroups mean we can feel confident recommending these medications to a wide range of patients without expecting dramatically different results based on age, race, BMI, or blood sugar levels.
For women, especially those in or past menopause, the data highlight an exciting opportunity: when clinically appropriate for symptom relief, MHT may enhance your weight-loss results when combined with GLP-1 therapy.
At Affinity Whole Health, we take a comprehensive, individualized approach. We carefully review your full health picture – including hormone levels – and create a plan that maximizes benefits while minimizing side effects. Many of our female patients already combine GLP-1 therapy with thoughtful hormone optimization when clinically indicated, and this new evidence reinforces why that combined strategy can be so effective.
Practical Takeaways
For everyone: GLP-1 medications are effective tools regardless of your age, race, ethnicity, or starting BMI. Pair them with resistance training, adequate protein intake, and consistent follow-up for the best long-term results.
For women: If you are postmenopausal or perimenopausal and experiencing symptoms, ask your provider about whether MHT could be a helpful addition to your GLP-1 regimen. We routinely evaluate this as part of our personalized protocols.
Monitoring matters: Regular check-ins help us track your progress, adjust dosing, and support sustainable lifestyle changes.
The Bottom Line
This large-scale analysis confirms that GLP-1 medications deliver reliable weight-loss benefits across diverse patient groups, with women experiencing a meaningfully greater response – likely tied to estrogen. Combined with emerging data on MHT for menopausal symptoms, we now have even stronger evidence that thoughtful hormone optimization can further enhance weight loss outcomes for many women.
If you’re already on a GLP-1 medication or considering one, these findings underscore why our comprehensive, patient-centered approach at Affinity Whole Health makes such a difference.
Ready to Optimize Your GLP-1 Journey? Our team specializes in GLP-1 therapy combined with personalized hormone evaluation. Whether you’re just starting or already seeing great results, we’re here to help you achieve the highest quality outcomes.
Schedule your consultation today to discuss how the latest evidence can work for you.
This is for informational purposes only and not medical advice. Individual results vary. Always consult your healthcare provider before starting, stopping, or changing any medication or treatment plan. Menopausal hormone therapy is prescribed only for symptom management and is not indicated solely for weight loss